Polymorphism of Transporter Genes Contributes to Variations in Treatment Outcomes and Adverse Events in Platinum Based- Chemotherapy- Treated Oral Cancer Patients

There are no good markers to identify drug-induced toxicity and clinical efficacy in advanced-stage oral cancer (OC), despite the existence of well-established first-line and induction chemotherapeutics. As a result, we investigated the impact of transporter genes in (Taxane/Platinum/5-fluorouracil) TPF or (Paclitaxel/Carboplatin) PC on clinical outcomes in OC patients. One hundred and twenty OC patients who had received fixed-dose TPF or PC were included in the current study. The transporter gene's polymorphism was evaluated using the PCR-RFLP method. The toxicity and progression-free survival of SNPs were also evaluated. There was a significant association in the gene ABCG2 (rs4693924) in both the wt/mt and mt/mt genotypes (p < .001). Meanwhile, dysphasia was significantly associated with SNPs rs943288 in ABCC4 in both wt/mt and mt/mt genotypes. A significant association was found for nausea with SNPs rs2804398 in ABCC2 (p = .008) and SNPs rs9332430 in ABCC1 (p = .001). However, there was no significant association observed between the genotypes of each SNP and progression-free survival (PFS). Clinical responses with progression-free survival and risk hazards were highly significant (p = .001). In conclusion, our data showed that the rs4693924 in ABCG2 anemia, ABCC2 (rs2804398) in diarrhea, ABCCC4 (rs943288) in dysphasia, and ABCC1 (rs9332430) in nausea were associated with individual adverse events.